What is the typical incidence of artesunate side effects?

How often do patients report side effects from artesunate?

Artesunate is an artemisinin derivative used to treat severe malaria. Side effects occur in roughly 1–5% of patients overall, with gastrointestinal issues like nausea, vomiting, and diarrhea being the most common. Neurological symptoms such as dizziness, headache, and ringing in the ears also appear in that range. Blood-related changes, including temporary drops in hemoglobin or reticulocyte counts, show rates between 5–20% in monitored groups. Cardiac effects are rare but include QTc prolongation that has observed rates of 2–3% under strict clinical supervision.

What causes these side effects mechanistically?

Artesunate generates reactive oxygen species that target parasite heme iron, but this process can also affect host cells with active iron metabolism. Gastrointestinal complaints arise from irritation of the intravenous or oral route. Neurological complaints are linked to neurotoxicity in animal models at high doses, but human clinical data remains limited. Blood changes are tied to hemolysis followed by bone marrow compensation.

What happens if side effects occur during treatment?

Treatment interruption occurs mainly when severe symptoms develop. Blood monitoring shows that hemoglobin drops often recover spontaneously after completion of the WHO recommended seven-day course. Cardiac monitoring is required in patients with pre-existing QTc issues. The drug remains safe for use in most patients when administered under hospital conditions.

When does the drug lose its effect after side effects?

The drug itself does not lose its effect. The drug remains active against malaria parasites even when complications like vomiting occur. Intravenous administration is preferred for severe cases where oral routes fail due to gastrointestinal problems.

How much does artesunate cost in the public sector?

Artesunate costs vary by region. In low-income countries, the WHO prequalified versions cost around $1–5 per treatment course. In the United States, the FDA-approved branded version (Artesunate for Injection) has prices ranging from $200–300 per dose.